Arthur Cole
Plus aucun poste en cours
Profil
Arthur Cole served as President & Chief Executive Officer at DiLab i Lund AB, Director at Sirigen Group Ltd., President at Visible Genetics, Inc., and Executive Vice President at Pharmacia LKB Biotechnology, Inc. He holds a doctorate degree from the University of London, which he received in 1978.
Anciens postes connus de Arthur Cole
Sociétés | Poste | Fin |
---|---|---|
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Directeur/Membre du Conseil | - |
Pharmacia LKB Biotechnology, Inc. | Corporate Officer/Principal | - |
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | President | - |
DiLab i Lund AB
DiLab i Lund AB Electronic Equipment/InstrumentsElectronic Technology DiLab AB offers instruments for automated blood sampling. The company was founded by Hans Axel Hansson in 1983 and is headquartered in Jonkopings lan, Sweden. | President | - |
Formation de Arthur Cole
University of London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 4 |
---|---|
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Health Technology |
DiLab i Lund AB
DiLab i Lund AB Electronic Equipment/InstrumentsElectronic Technology DiLab AB offers instruments for automated blood sampling. The company was founded by Hans Axel Hansson in 1983 and is headquartered in Jonkopings lan, Sweden. | Electronic Technology |
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Process Industries |
Pharmacia LKB Biotechnology, Inc. |